The clinical effectiveness and cost-effectiveness of vinorelbine for breast cancer: a systematic review and economic evaluation.
Lewis
R
R
NHS Centre for Reviews and Dissemination, University of York, UK.
Bagnall
A-M
AM
King
S
S
Woolacott
N
N
Forbes
C
C
Shirran
L
L
Duffy
S
S
Kleijnen
J
J
ter Riet
G
G
Riemsma
R
R
D000972:Antineoplastic Agents, Phytogenic / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy / Q000473:pathology; D003362:Cost-Benefit Analysis; D005260:Female; D006801:Humans; D019057:Quality-Adjusted Life Years; D016032:Randomized Controlled Trials as Topic; D016896:Treatment Outcome; D014747:Vinblastine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000191:economics / Q000627:therapeutic use; D000077235:Vinorelbine
D000972:Antineoplastic Agents, Phytogenic; D014747:Vinblastine; D000077235:Vinorelbine